Pneumatosis

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Retrieved on: 
Wednesday, August 12, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, RTT, Medicine, Medical specialties, Pulmonary fibrosis, Clinical medicine, Interstitial lung disease, Fibrosis, Usual interstitial pneumonia, Pneumatosis

In some cases, fibrosis which involves scarring and damage to the lungs can develop.

Key Points: 
  • In some cases, fibrosis which involves scarring and damage to the lungs can develop.
  • This can lead to a significant impact on the daily life of those affected, as well as their families, including high morbidity and mortality.
  • Some children with interstitial lung disease may develop serious fibrosis that progresses, said the coordinating investigator Prof. Robin Deterding, M.D., Director of the Breathing Institute, Children's Hospital Colorado.
  • This study represents our ongoing commitment to address unmet needs and advance research for adult and pediatric patients living with pulmonary fibrosis.

VIDA Partners With TeraRecon, Inc. For Distribution Of AI-Powered Lung Analysis

Retrieved on: 
Monday, October 14, 2019
Pulmonology, Respiratory diseases, Otorhinolaryngology, Organ systems, Occupational diseases, Obstructive lung disease, Respiratory therapy, Respiratory disease, Interstitial lung disease, Lung, Chronic obstructive pulmonary disease, Pneumatosis

CORALVILLE, Iowa, Oct. 14, 2019 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing.

Key Points: 
  • CORALVILLE, Iowa, Oct. 14, 2019 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing.
  • By precisely quantifying lung characteristics in a chest CT scan, LungPrint helps providers detect COPD and other interstitial lung disease earlier, often when debilitating symptoms have yet to occur.
  • Early detection of chronic lung disease is reported to elongate life expectancies and reduce overall healthcare costs ( Larsson, et.
  • VIDA's LungPrint solution aims to provide greater precision and personalization across a range of lung diseases including lung cancer, obstructive airway diseases like emphysema and asthma, and interstitial lung disease.

Bayer, Brigham and Women's Hospital, Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases

Retrieved on: 
Tuesday, September 24, 2019
Pulmonology, Medicine, Respiratory therapy, Respiratory diseases, Chronic lower respiratory diseases, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease, Chronic obstructive pulmonary disease, Interstitial lung disease, Chronic condition, Pneumatosis, Obstructive lung disease

BERLIN and BOSTON, Sept. 24, 2019 /PRNewswire/ -- Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to research new drug candidates to treat chronic lung diseases.

Key Points: 
  • BERLIN and BOSTON, Sept. 24, 2019 /PRNewswire/ -- Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to research new drug candidates to treat chronic lung diseases.
  • Chronic lung disease is a broad term for a number of diseases of the airways and other structures of the lung, including chronic obstructive pulmonary disease (COPD).
  • "The joint lab concept continues to be an innovative model for collaboration between academia and industry, enabling novel approaches to drug discovery."
  • Bayer is researching a wide range of lung diseases, including interstitial lung disease, chronic obstructive pulmonary disease, pulmonary arterialhypertension, persistent chronic cough and obstructive sleep apnea.